Comments
Syngene International on Monday signed a research and development agreement with global healthcare company GSK. As part of the agreement, Syngene will set up a customised discovery research laboratory to support projects across several therapeutic areas.
A team of Syngene scientists will work closely with GSK’s global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world’s most pressing healthcare needs. Shares of Syngene jumped 3.18 per cent at ₹584 on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.